U.S. researchers say Axonyx's Posiphen was found to improve the ability of transplanted human neuronal stem cells to change into neurons in biotech mice. They say the Phase I trial drug appears to suppress the amyloid precursor protein, allowing new neurons to be produced in the brain, a critical development toward a stem cell therapy for Alzheimer's.

Related Summaries